Details

Autor(en) / Beteiligte

• Byrd, John C
• Brown, Jennifer R
• O'Brien, Susan
• Barrientos, Jacqueline C
• Kay, Neil E
• Reddy, Nishitha M
• Coutre, Steven
• Tam, Constantine S
• Mulligan, Stephen P
• Jaeger, Ulrich
• Devereux, Steve
• Barr, Paul M
• Furman, Richard R
• Kipps, Thomas J
• Cymbalista, Florence
• Pocock, Christopher
• Thornton, Patrick
• Caligaris-Cappio, Federico
• Robak, Tadeusz
• Delgado, Julio
• Schuster, Stephen J
• Montillo, Marco
• Schuh, Anna
• de Vos, Sven
• Gill, Devinder
• Bloor, Adrian
• Dearden, Claire
• Moreno, Carol
• Jones, Jeffrey J
• Chu, Alvina D
• Fardis, Maria
• McGreivy, Jesse
• Clow, Fong
• James, Danelle F
• Hillmen, Peter

Titel

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

Ist Teil von

• The New England journal of medicine, 2014-07, Vol.371 (3), p.213-223

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In this trial, patients with previously treated and relapsed chronic lymphoid leukemia who received ibrutinib had significantly improved progression-free survival, overall survival, and response rate, as compared with those who received ofatumumab. Chronic lymphoid leukemia (CLL) is characterized by a variable natural history that is partly predicted by clinical and genomic features. 1 Therapy for CLL has evolved from monotherapy with alkylating agents to chemoimmunotherapy. 2 , 3 Each of the combination regimens has shown prolonged rates of progression-free survival, as compared with similar regimens that do not contain antibodies. Treatment of patients with relapsed CLL often includes regimens such as bendamustine and rituximab, 4 ofatumumab, 5 or investigational agents. 6 – 8 Ofatumumab was approved by the Food and Drug Administration (FDA) and the European Medicines Agency on the basis of a single-group study involving patients who had . . .